Is ozanimod on the market?

In March 2020, the U.S. Food and Drug Administration(FDA) approved ozanimod for the treatment of relapsing multiple sclerosis in adults. The European Commission approved ozanimod in May 2020 for the treatment of adult patients with relapsing-remitting multiple sclerosis who have active disease as defined by clinical or imaging features. The FDA approved Ozamod on May 27, 2021, for the treatment of adults with moderately to severely active ulcerative colitis.

Multiple sclerosis is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects, and inflammatory bowel disease is a chronic inflammatory disease that can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. Ozamodis a once-daily sphingosine1-phosphate receptor modulator that reduces circulating lymphocytes that contribute to multiple sclerosis-related neuroinflammation, reduces debilitating symptoms, and may reduce disease progression. In clinical trials, Ozamod reduced multiple sclerosis-related brain volume loss in several areas. Ozamod leads to peripheral lymphocyte sequestration and reduces circulating lymphocytes in the gastrointestinal tract.

In 2023, the original drug Ozamod has been approved by the National Medical Products Administration and will be launched in China. However, it has not been included in the medical insurance list for a short time. The specific price is not yet clear, and domestic purchase channels are relatively difficult. The price of Ozamod original drug specifications0.92*28 capsules per box listed overseas may be around 19,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There is currently no generic version of Ozamod produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.